硝苯地平与苯磺酸氨氯地平治疗肥胖合并高血压患者的效果对比

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the effects of Nifedipine and Amlodipine Besylate in the treatment of patients with obesity and hypertension.Methods A total of 60 cases of patients with obesity and hypertension who were treated in our hospital from January 2017 to January 2018 were selected for the study and were divided into study group(n=30)and control group (n=30)according to random number table method.Study group was given Amlodipine Besylate,and control group was given Nifedipine,and the two groups were treated for 4 week.The blood lipids(triglyceride[TG],total cholesterol[TC],high density lipoprotein cholesterol[HDL-C],low density lipoprotein cholesterol[LDL-C]),blood glucose(fasting plasma glucose[FPG],fasting insulin[FIns])and blood pressure(systolic blood pressure[SBP],diastolic blood pressure [DBP])were compared between the two groups before treatment and after 4 week of treatment,and the treatment effects and the occurrence of adverse reactions were recorded.Results There was no significant difference in each index between the two groups before treatment(P＞0.05).After 4 week of treatment,the incidence rate of adverse reactions in study group was lower than that in control group(6.67%vs.23.33%)(χ2=3.890,P=0.049),while the total effective rate in study group was higher than that in control group(96.67%vs.80.00%)(χ2=4.750,P=0.029).After 4 week of treatment,the levels of DBP and TC,TG,LDL-C,HDL-C were lower than those before treatment(P<0.05).The levels of DBP and TC,TG,LDL-C，HDL-C in study group after treatment were lower than those in control group (P<0.05).The blood glucose FPG,FIns value and blood pressure SBP after 4 week of treatment in the two groups were not significantly different from those before treatment(P＞0.05).Conclusion Nifedipine and Amlodipine Besylate both can effectively lower blood pressure,and the latter one has better antihypertensive efficacy and has more obvious effects on blood lipids,blood pressure and blood glucose,and it has lower incidence rate of adverse reactions than the former one.

Key words： Nifedipine Amlodipine Besylate Hypertension Obesity

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LONG Fei-long
	YE Jun
	HUANG Ai-hua

Cite this article:

LONG Fei-long,YE Jun,HUANG Ai-hua. Effects comparison of Nifedipine and Amlodipine Besylate in the treatment of patients with obesity complicated with hypertension[J]. 中国当代医药, 2018, 25(20): 50-53.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I20/50

[1]	陈岚，任骞，徐进，等.苯磺酸左旋氨氯地平对原发性高血压患者血管内皮功能的影响[J].陕西医学杂志，2016，45（2）：241-242.
[2]	王海焱，刘铜华.中药复方治疗2型糖尿病胰岛素抵抗的研究[J].西部中医药，2017，30（5）：137-140.
[3]	刘玉英，张彬，王木华，等.氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的疗效观察[J].中国医药导刊，2016，18（9）：927-928.
[4]	王文.对2009年基层版《中国高血压防治指南》的解读[J].内科急危重症杂志，2010，16（3）：116-119.
[5]	黄玉艳，孙静，陈秀清，等.糖尿病患者不同体质量指数对高血压发病的影响[J].山东医药，2017，57（2）：25-28.
[6]	周燕斌，谢灿茂，肖海鹏，等.肥胖症伴阻塞性睡眠呼吸暂停与胰岛素抵抗及高胰岛素血症的关系[J].中华内分泌代谢杂志，2002，18（3）：181-183.
[7]	徐子迪，刘敏，梁学军，等.奥曲肽对先天性高胰岛素血症26 例疗效分析[J].中国糖尿病杂志，2016，8（11）：667-671.
[8]	樊永旺，马骏，邱健，等.不同肥胖指标对冠心病、高血压及其合并糖尿病患者患病风险的评估作用[J].山东医药，2017，57（1）：11-14.
[9]	石伟龙.高血压患者联合用药：ACEI/ARB和CCB的基础上加用利尿剂还是β受体阻滞剂[J].临床药物治疗杂志，2017，15（12）：77.
[10]	吕新才，张标，戎成振，等.钙离子拮抗剂联合他汀类对高血压老年患者的疗效[J].心血管康复医学杂志，2017，26（3）：306-310.
[11]	史振仙，李龙，胡敏，等.叶酸联合钙离子拮抗剂治疗老年高血压患者对血压、同型半胱氨酸等水平的影响[J].疑难病杂志，2016，15（10）：1006-1009.
[12]	李晓明，商睿，郝盼盼.苯磺酸氨氯地平与缬沙坦逆转左心室肥厚疗效的对比研究[J].中华全科医学，2016，14（8）：1330-1331.
[13]	常瑛，文爱东，李昌炜，等.复方苯磺酸氨氯地平/阿托伐他汀钙片的人体药动学[J].中国医院药学杂志，2008，28（19）：1672-1676.
[14]	陈慧敏，许逸飞.苯磺酸氨氯地平联合阿托伐他汀钙治疗老年高血压伴血脂异常的临床研究[J].中国临床药理学杂志，2016，32（12）：1072-1074.
[15]	果秋婷，张小飞.HPLC法同时测定复方阿托伐他汀钙苯磺酸氨氯地平片中两种药物的含量[J].中国药师，2016，19（3）：610-613.
[16]	杨若娟，吕吉元.依那普利叶酸联合苯磺酸氨氯地平治疗H型高血压的疗效分析[J].中西医结合心脑血管病杂志，2016，14（10）：1149-1150.
[17]	石国素，路运华.硝苯地平联合酚妥拉明及硫酸镁治疗妊娠高血压疾病的临床疗效[J].医学综述，2016，22（2）：386-388.
[18]	张艳，徐珂.硝苯地平联合倍他乐克对原发性高血压患者的疗效观察[J].药物评价研究，2016，39（4）：648-651.